HQL - New Innovation Spurring A Biotech Rejuvenation
By Evan McCulloch, Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund
Franklin Equity Group's Evan McCulloch explains why higher rates of drug utilization and healthcare spending are lending support to the biotechnology and healthcare industries. He also gives his take on recent medical breakthroughs he thinks are likely to drive future growth.
Since hitting an all-time high in July 2015, biotech stocks, as measured by the NASDAQ Biotechnology Index, have lagged the S&P 500 Index.1 The biotech index has rebounded off November 2016 lows, but concerns